Preoperative serum inhibin levels in patients with ovarian tumors

Journal of Obstetrics and Gynaecology Research

Volumn 30, Issue 2, 2004, Pages 155-161

  El Shalakany, Amr ^a,c   Abou Talib, Yasser ^a   Shalaby, Hatem Saad ^a   Sallam, Maha ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Ain Shams University   (Egypt)

^c NONE   (Egypt)

Author keywords

Inhibin; Ovarian tumors; Preoperative

Indexed keywords

CA 125 ANTIGEN; INHIBIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASCITES; BENIGN TUMOR; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; FOLLICULAR PHASE; HUMAN; MEDICAL SPECIALIST; MENOPAUSE; MENSTRUAL CYCLE; OVARY CANCER; OVARY TUMOR; PATIENT COUNSELING; PATIENT REFERRAL; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; HUMANS; INHIBINS; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREOPERATIVE CARE; SENSITIVITY AND SPECIFICITY;

EID: 1942518253     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2003.00176.x     Document Type: Article

References (26)

1. Poveda A. Advanced ovarian cancer; update, remarks and conclusions on optimal therapy. Int J Gynecol Cancer 2000; 10 (Suppl. 1): 57-60.
2. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-980.
3. Randall TC, Rubin SC. Cytoreductive surgery for ovarian cancer. Surg Clinics North Am, Gynecologic Oncol 2001; 81: 871-883.
4. DiSaia PJ, Tewari KS. Recent advancements in the treatment of epithelial ovarian cancer. J Obstet Gynecol Res 2001; 27: 61-75.
5. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994; 70: 363-370.
6. Einhorn N, Bast RC, Knapp RC, Tjenberg B, Zurawski VR. Preoperative evaluation of serum CA-125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986; 67: 414-416.
7. Cruickshank DJ, Fullerton WT, Klopper A. The clinical significance of preoperative CA-125 in ovarian cancer. Br J Obstet Gynaecol 1987; 94: 692-694.
8. Malkaiasn GD, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA-125 levels in premenopausal and post-menopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 516-518.
9. Patsner B, Mann WJ. The value of preoperative serum CA-125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988; 159: 873-876.
10. Thesis. El-Shalakany AH. Predictive value of serum CA125 in patients with ovarian masses (MD Thesis). Cairo: Ain Shams University, 1992.
11. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinkas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97: 922-929.
12. Aslam A, Tailor A, Lawton F, Carr J, Savvas M, Jurkovic D. Prospective evaluation of three different models for the preoperative diagnosis of ovarian cancer. BJOG 2000; 107: 1347-1353.
13. Kingsley DM. The TGF-B superfamily: new members, new receptors and new genetic tests of functions in different organisms. Genes Dev 1994; 8: 133-146.
14. Knight PG, Groome N, Beard AJ. Development of a two-site immunoradiometric assay for dimeric inhibin using antibodies against the chemically synthesized fragments of the α and β subunits. J Endocrinol 1991; 129: 9-12.
15. Tierney ML, Goss NH, Tomkins SM. Physicochemical and biological characterization of recombinant human inhibin A. J Endocrinol 1990; 126: 3268-3270.
16. Fuller PJ, Chu S, Jobling T, Mamers P, Healy DL, Burger HG. Inhibin subunit gene expression in ovarian cancers. Gynecol Oncol 1999; 73: 273-279.
17. Zheng W, Lu JJ, Luo F et al. Tumor stroma as the main source of inhibin production in ovarian epithelial tumors. Am J Reprod Immunol 2000; 44: 104-113.
18. Burger HG, Baillie A, Drummond AE et al. Inhibin and ovarian cancer. J Reprod Immunol 1998; 39: 77-87.
19. Hermann UJ, Locher GW, Goldhirsch A. Sonographic patterns of ovarian tumors, prediction of malignancy. Obstet Gynecol 1987; 69: 777-781.
20. Trimbos JB. Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer 2000; 10 (Suppl. 1): 8-11.
21. Lambert-Messerlian GM, Steinhoff M, Zheng W et al. Multiple immunoreactive inhibin proteins in serum from post-menopausal women with epithelial ovarian cancer. Gynecol Oncol 1997; 65: 512-516.
22. Burger HG, Robertson DM, Cahie N et al. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumors. Clin Endocrinol (Oxford) 1996; 44: 413-418.
23. Menon U, Riley SC, Thomas J et al. Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG 2000; 107: 1069-1074.
24. Robertson DM, Cahir N, Burger HG, Mamers P, Groome N. Inhibin forms in serum from postmenopausal women with ovarian cancer. Clin Endocrinol 1999; 50: 381-386.
25. Robertson DM, Cahir N, Burger HG et al. Combined inhibin and CA125 assay in the detection of ovarian cancer. Clin Chem 1999; 45: 651-658.
26. Robertson DM, Stephenson T, Pruysers E, et al. Characterization of inhibin forms and their measurement by an alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer. J Clin Endocrinol Metabolism 2002; 87 (2): 816-824.